ICS Members Only
Join ICS Sign in
{{CC.VideoPaywallHeaderText}}
{{CC.VideoPaywalButtonText}} Sign in Sign in
{{CC.VideoPaywallHeaderText}}
{{CC.VideoPaywalButtonText}} Sign in

To register for this workshop please email reg_ics22@kenes.com

{{CC.VideoPaywallHeaderText}}
Purchase Gold Pass Register Sign in
Prefer to watch at your own pace, catch up on what you missed or re-watch your favourite sessions?
Extend your access to all state of the art and scientific meeting content for an extra three months, until 13 December 2022.

To purchase the gold pass please email reg_ics22@kenes.com
Restricted Video
Sign in
Home

The Use of Novel Soluble Guanylate Cyclase Activators to Treat Benign Prostatic Hyperplasia, Obstruction and Fibrosis - Mechanistic Concepts and Clinical Implications

13/07/2024 00:45:23

Workshop Schedule

Karl-Erik Andersson
Anthony John Kanai
Lori A Birder
Christopher Henry Fry
All

Aims & Objectives

Advanced
90 minutes
Male Lower Urinary Tract Symptoms (LUTS) / Voiding Dysfunction
Pure and Applied Science / Translational
BPH/BOO/LUTS sGC Activators PDE5 Inhibitors
Urology, Basic Science

BPH can result in bladder outflow obstruction and development of LUTS, and by 80 yrs of age is present in about 75% of men. Pharmacological therapies include alpha-adrenoceptor antagonists, 5-alpha reductase inhibitors, and the PDE5 inhibitor, tadalafil. The efficacy of tadalafil suggests a role for nitric oxide (NO•) through activation of soluble guanylate cyclase (sGC) and production of cGMP - a smooth muscle relaxant, but also an antifibrotic agent. However, patients can become refractory to tadalafil due to nitrergic nerve damage, or sGC inactivation from oxidative stress. We will discuss how sGC activators augment cGMP production under conditions when the NO• pathway is compromised to manage BPH, LUTS and fibrotic development.